There are no effective treatments for intracerebral hemorrhage (ICH), which has a 30% to 40% mortality rate
Intranasal anti-CD3 mAb treatment showed a reduction in Intracerebral Hemorrhage injury severity
Intranasal foralumab could represent a novel therapeutic approach for treating ICH and potentially other types of acute brain injury
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced broad-based findings on the utility of nasal anti-CD3 mAb in the treatment of intracerebral hemorrhage (ICH). The data using a mouse model of collagenase-induced ICH was presented at the Annual American Academy of Neurology conference. The full presentation can be viewed at https://www.aan.com/MSA/Public/Events/AbstractDetails/52974 until May 14, 2023.
https://finance.yahoo.com/news/tiziana-life-sciences-announces-findings-110000491.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.